In the ALEX trial, which compared alectinib to crizotinib as first-line treatments in patients with advanced ALK-positive NSCLC, the mPFS was 34.8 months for alectinib versus 10.9 months for crizotinib (HR = 0.43, 95% CI 0.32–0.58) [63]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.